Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) is the most common form of hereditary cerebral small vessel disease, with no proven
disease-modifying treatments. Adrenomedullin, a vasoactive peptide, has angiogenic,
vasodilation, anti-inflammatory, and anti-oxidative properties and could have triple sites of
action on components of the neuro-glial-vascular unit consisting of vessels, microglia and
oligodendrocytes or, more specifically, on the white matter oligovascular unit. The aim of
the AMCAD trial is to assess the safety and efficacy of Adrenomedullin in CADASIL patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Cerebral and Cardiovascular Center, Japan